Is this stock the next Moderna?

Rarely does opportunity knock twice. This may be one of those rare instances. Here's a conviction buy from the 40-year pharma marketing industry veteran who recommended Moderna at $21.

Om Podcasten

This podcast is ideal for accredited investors seeking alpha (above market) returns from conventional and alternative investment classes including stocks, options, futures, Angel, seed, mini-VC, private borrowing and lending, and real estate (especially multi-family rentals. Content is extended for educational and informational purposes only and is not intended to be nor should it be construed as investment advice. Consult with your investment professional and other members of your professional advisory team before making any investments based on the content of this podcast.